About
Technology
Issues
FAQ
Links
Official Page
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the
DEPICT
‐2 study): 52‐week results from a randomized controlled trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.